BPC-157 in the UAE: mechanisms, the evidence, and how it is assessed in Dubai

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a fragment of a gastric protective protein originally isolated from human gastric juice by Sikiric and colleagues in 1993. It has been the subject of more than 100 peer-reviewed publications across rodent and in vitro tissue-repair models.

For UAE-based researchers, the complete reference covering mechanism, tendon and GI research, peptide pen format, CoA standards, and Dubai sourcing is now consolidated in the Baseline BPC-157 pillar guide.

Read the complete BPC-157 reference guide for the verified citation list, the four mechanistic threads (nitric oxide, angiogenesis, FAK-paxillin, GI cytoprotection), and the eight FAQ entries on sourcing and storage.

• Chemical class: synthetic pentadecapeptide, 15 residues, molecular mass approximately 1419.5 Da
• Original source: derived from a fragment of a gastric protective protein in human gastric juice
• Clinical-trial designation: PL14736 (early Pliva inflammatory bowel disease work)
• Approval status: not approved as a pharmaceutical in any jurisdiction; supplied as a research peptide
• Baseline format: pre-filled BPC-157 and TB-500 combination pen with per-batch CoA at /uae/peptides/bpc157-tb500-32

Comparison with TB-500 and the combination protocol are covered in BPC-157 vs TB-500 research applications compared and the combination pillar at /uae/guides/bpc-157-tb-500.

Baseline does not sell compounds. A consultation decides whether a program is appropriate, supplies it where it is, and monitors it. Nothing here is a diagnosis or a treatment plan. Nothing in this article constitutes medical advice.